HER2-low expression in breast cancer

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markersПодробнее

Emerging Experts: A Discussion With Tarantino on HER2-Low Breast Cancer and Antibody-Drug ConjugatesПодробнее

Latest Update on HER2-Low Breast Cancer and Implications for Clinical PracticeПодробнее

Gaining an Enhanced Understanding of HER2 Expression in Breast CancerПодробнее

AI technology for interpretation of HER2 Low and practical application in the real-world settingПодробнее

Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?Подробнее

Dr. Elena Provenzano Unveils the Future of AI in HER2 Low Interpretation at USCAP 2024Подробнее

Optimizing the Identification of HER2-Low Breast Cancer (Video Lecture)Подробнее

DESTINY-Breast06 trial in HER2 LOW and HER2 ULTRA LOW metastatic breast cancer.Подробнее

Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugateПодробнее

Clinical Implications of ‘Low’ HER2 Expression: 2023 Best of Breast ConferenceПодробнее

Overview of the management of HER2-low breast cancer patientsПодробнее

HER2-low breast cancer: the ESMO Expert Consensus StatementsПодробнее

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysisПодробнее

HER2-Low Breast Cancer: DESTINY or Good Science?Подробнее

[SHKH 10.2023] BIỂU HIỆN “HER2-LOW” VÀ “ER-LOW”TRONG UNG THƯ VÚПодробнее

How to Treat Estrogen Receptor-Low Breast Cancer: All You Need to KnowПодробнее

Updates on HER2-low breast cancerПодробнее

SSMC- Abu Dhabi Surgical Pathology Journal Club: HER2-low/1+ in Breast CancerПодробнее

Understanding HER2-Low Breast Cancer: New Insights and Treatment OptionsПодробнее